Special Issue

Vaccines and Other Prophylactic Interventions Against H5N1 Influenza Viruses

Message from the Guest Editors

In this Special Issue, entitled "Vaccines and Other Prophylactic Interventions Against H5N1 Influenza Viruses", we welcome submissions of original research, reviews, clinical trials, and opinion articles that shed light on the latest advances in the field of vaccines and other prophylactic interventions against HPAIV H5N1, with a particular emphasis on the following:

- Protection/efficacy of current vaccines;
- Generation of safe, immunogenic, and protective new vaccine candidates:
- Environmental and other factors affecting effectiveness of vaccines;
- Limitations of influenza vaccination;
- Vaccine adjuvants and immunomodulators;
- Evaluation of vaccine efficacy;
- Vaccine delivery methods and strategies;
- Early implementation of prevention policies.

Guest Editors

Dr. Ahmed Mostafa

Dr. Aitor Nogales

Prof. Dr. Luis Martinez-Sobrido

Deadline for manuscript submissions

31 December 2025



an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/225800

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

mdpi.com/journal/vaccines





an Open Access Journal by MDPI

Impact Factor 3.4 CiteScore 9.9 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).

